Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glioblastoma Multiforme: early-phase trial registry
37 of 89 indexed Glioblastoma Multiforme trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #154 of 28,707 conditions by registered trial count.
89 US clinical trials · 37 currently recruiting · #154 of 28,707 conditions by registered trial count
Glioblastoma Multiforme: 89 US clinical trials tracked, 37 recruiting.
Glioblastoma Multiforme is the subject of 89 registered US clinical trials on ClinicalTrials.gov, 37 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Northwell Health, running 6 of these trials.
Enrollment posture brief
Registry condition glioblastoma-multiforme
OPEN 37 | RECR 42% | LATE 1 | EARLY 74 | RANK #154 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Post Traumatic Stress Disorder (42% recruiting · 265 trials)
Glioblastoma Multiforme lists 37 open slots (42% of 89 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glioblastoma Multiforme on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glioblastoma Multiforme recruits in line with its size-band peers.
37 of 89 indexed trials (41.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glioblastoma Multiforme trials is spread across many organizations.
Northwell Health accounts for 6 of 89 trials (6.7%). 61 distinct sponsors appear on at least one study for this condition label.
-
Most Glioblastoma Multiforme trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 89 trials that report a genuine target (sentinel values excluded). 72 of those (80.9%) plan for fewer than 100 participants.
-
Glioblastoma Multiforme research is mostly interventional.
80 interventional and 9 observational studies make up this index (89.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
89 total, page 2 of 2
Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma
Nader Sanai
NCT05076513
Trial of Dichloroacetate (DCA) in Glioblastoma Multiforme (GBM)
University of Florida
NCT05120284
Study of DSP-0390 in Patients With Recurrent High-Grade Glioma
Sumitomo Pharma America
NCT05023551
IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma
University of Florida
NCT05353530
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Children's Oncology Group
NCT04978727
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
Pediatric Brain Tumor Consortium
NCT03389802
A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)
Acerta Pharma
NCT02586857
A Safety Study of Pharmacologic Ascorbate and Ferumoxytol in Addition to Standard of Care Chemoradiation in Glioblastoma
Bryan Allen
NCT04900792
Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Oblato
NCT05561374
Trial of Anti-Tim-3 in Combination With Anti-PD-1 and SRS in Recurrent GBM
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03961971
Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM
Northwell Health
NCT03630289
Spatiotemporal Dimensions of Metabolism in Autochthonous Tumors of GBM Patients
AdventHealth Translational Research Institute
NCT06054529
Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma
Celgene
NCT01177397
A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas
National Cancer Institute (NCI)
NCT00995007
Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme
SCRI Development Innovations
NCT01349660
Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor)
EMD Serono
NCT00093964
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
M.D. Anderson Cancer Center
NCT00504660
Ph. II Temozolomide + O6-BG in Treatment of Pts w Temozolomide-Resistant Malignant Glioma
Duke University
NCT00613093
PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation
Brown University
NCT01402063
PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma
Massachusetts General Hospital
NCT01112527
Phase 2 Study MPC-6827 for Recurrent Glioblastoma Multiforme
Myrexis
NCT00892931
Temozolomide Chronotherapy for High Grade Glioma
Washington University School of Medicine
NCT02781792
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
Katy Peters
NCT00979017
Dose Confirmation Study of Cotara for the Treatment of Glioblastoma Multiforme at First Relapse
Peregrine Pharmaceuticals
NCT00677716
A Study of Ad-RTS-hIL-12 With Veledimex in Subjects With Glioblastoma or Malignant Glioma
Alaunos Therapeutics
NCT02026271
A Dose Per Fraction Escalation Trial of Hypofractionated IMRT With Temozolomide for Newly Diagnosed Glioblastoma
University of Colorado, Denver
NCT00792012
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Julie Krystal
NCT01837862
AMG 102 and Avastin for Recurrent Malignant Glioma
Katy Peters
NCT01113398
Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
NCT02715609
AMG 595 First-in-Human in Recurrent Gliomas
Amgen
NCT01475006
A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma
Tracon Pharmaceuticals
NCT01564914
AZD8055 for Adults With Recurrent Gliomas
National Cancer Institute (NCI)
NCT01316809
Dose Escalation Study to Determine the Safety of IFN-Beta Gene Transfer in the Treatment of Grade III & Grade IV Gliomas
Biogen
NCT00031083
Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma
Northwell Health
NCT00301418
Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Monteris Medical
NCT00747253
Cellular Immunotherapy Study for Brain Cancer
Jonsson Comprehensive Cancer Center
NCT01144247
Cancer Stem Cell High-Throughput Drug Screening Study
Swedish Medical Center
NCT02654964
GW572016 to Treat Recurrent Malignant Brain Tumors
National Cancer Institute (NCI)
NCT00107003
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma
National Cancer Institute (NCI)
NCT03027388
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 26 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Glioblastoma Multiforme records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glioblastoma Multiforme trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glioblastoma Multiforme page
89 registered trials, 37 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 37 Glioblastoma Multiforme trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Northwell Health sponsors the most Glioblastoma Multiforme trials on record, review their full trial history before evaluating a specific study. See Northwell Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glioblastoma Multiforme condition card totals 89 registered trials; most-linked intervention Temozolomide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.